<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9</volume><submitter>Wertenauer C</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Rapid diagnostic testing for SARS-Cov-2 antigens is used to combat the ongoing pandemic. In this study we aimed to compare two RDTs, the SD Biosensor Q SARS-CoV-2 Rapid Antigen Test (Roche) and the Panbio COVID-19 Ag Rapid Test (Abbott), against rRT-PCR.&lt;h4>Methods&lt;/h4>We included 2,215 all-comers at a diagnostic center between February 1 and March 31, 2021. rRT-PCR-positive samples were examined for SARS-CoV-2 variants.&lt;h4>Findings&lt;/h4>Three hundred and thirty eight participants (15%) were rRT-PCR-positive for SARS-CoV-2. The sensitivities of Roche-RDT and Abbott-RDT were 60.4 and 56.8% (&lt;i>P&lt;/i> &lt; 0.0001) and specificities 99.7% and 99.8% (&lt;i>P&lt;/i> = 0.076). Sensitivity inversely correlated with rRT-PCR-Ct values. The RDTs had higher sensitivities in individuals referr</pubmed_abstract><journal>Frontiers in medicine</journal><pagination>774550</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8979030</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Diagnostic Performance of Rapid Antigen Testing for SARS-CoV-2: The COVid-19 AntiGen (COVAG) study.</pubmed_title><pmcid>PMC8979030</pmcid><pubmed_authors>Marz W</pubmed_authors><pubmed_authors>Mutschmann C</pubmed_authors><pubmed_authors>Moissl AP</pubmed_authors><pubmed_authors>Hauser U</pubmed_authors><pubmed_authors>Wertenauer C</pubmed_authors><pubmed_authors>Wieland E</pubmed_authors><pubmed_authors>Mayer C</pubmed_authors><pubmed_authors>Wertenauer HJ</pubmed_authors><pubmed_authors>Brenner Michael G</pubmed_authors><pubmed_authors>Roskos M</pubmed_authors><pubmed_authors>Dressel A</pubmed_authors><pubmed_authors>Pfeifer C</pubmed_authors><pubmed_authors>Lorkowski S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Diagnostic Performance of Rapid Antigen Testing for SARS-CoV-2: The COVid-19 AntiGen (COVAG) study.</name><description>&lt;h4>Background&lt;/h4>Rapid diagnostic testing for SARS-Cov-2 antigens is used to combat the ongoing pandemic. In this study we aimed to compare two RDTs, the SD Biosensor Q SARS-CoV-2 Rapid Antigen Test (Roche) and the Panbio COVID-19 Ag Rapid Test (Abbott), against rRT-PCR.&lt;h4>Methods&lt;/h4>We included 2,215 all-comers at a diagnostic center between February 1 and March 31, 2021. rRT-PCR-positive samples were examined for SARS-CoV-2 variants.&lt;h4>Findings&lt;/h4>Three hundred and thirty eight participants (15%) were rRT-PCR-positive for SARS-CoV-2. The sensitivities of Roche-RDT and Abbott-RDT were 60.4 and 56.8% (&lt;i>P&lt;/i> &lt; 0.0001) and specificities 99.7% and 99.8% (&lt;i>P&lt;/i> = 0.076). Sensitivity inversely correlated with rRT-PCR-Ct values. The RDTs had higher sensitivities in individuals referr</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-04T23:34:41.081Z</modification><creation>2025-04-04T23:34:41.081Z</creation></dates><accession>S-EPMC8979030</accession><cross_references><pubmed>35386920</pubmed><doi>10.3389/fmed.2022.774550</doi></cross_references></HashMap>